Skip to main content
Top
Published in: Digestive Diseases and Sciences 2/2018

01-02-2018 | Stanford Multidisciplinary Seminars

Growing Concerns: A 3-Year-Old Girl with Multiple Hepatic Masses and Gastrointestinal Bleeding

Authors: Christine Yang, Adam Gomez, Anshul Haldipur, William Berquist, Dorsey Bass

Published in: Digestive Diseases and Sciences | Issue 2/2018

Login to get access

Excerpt

A 5-month-old female was observed to have massive hematemesis 48 h after surgical closure of a patent ductus arteriosus. Her prior medical history was significant for: intrauterine growth retardation, with a birth weight of 2 kg; delivery through a scheduled Cesarean section due to breech presentation; and a maternal history of antiphospholipid antibodies and thrombophilia with six prior miscarriages. An esophagogastroduodenoscopy (EGD) was performed emergently at the bedside; although the examination was limited due to respiratory instability, it was grossly normal except for a large portion of the stomach being obscured by a clot. Although she was initially stabilized, she had an acute drop in hemoglobin four days later. An abdominal ultrasound demonstrated cavernous transformation of the porta hepatis without visualization of portal vein, corroborated by magnetic resonance imaging (MRI), which additionally revealed esophageal and rectal varices and splenomegaly (Fig. 1a). Repeat EGD demonstrated multiple grade 4 varices in the distal esophagus (Fig. 2a). After receiving sclerotherapy to the largest varices, she had no further bleeding and was discharged home. Since an evaluation for hypercoagulability during admission was negative, it was presumed that at some point she may have developed a portal vein thrombus from maternal transfer of antiphospholipid antibodies with subsequent portal hypertension, though no thrombus was ever visualized by imaging.
Literature
1.
go back to reference Zhang HY, Li WB, Ye H, Xiao ZY, Peng YR, Wang J. Long-term results of the paraesophagogastric devascularization with or without esophageal transection: which is more suitable for variceal bleeding? World J Surg. 2014;38:2105–2112.CrossRefPubMed Zhang HY, Li WB, Ye H, Xiao ZY, Peng YR, Wang J. Long-term results of the paraesophagogastric devascularization with or without esophageal transection: which is more suitable for variceal bleeding? World J Surg. 2014;38:2105–2112.CrossRefPubMed
2.
go back to reference Hassed S, Li S, Mulvihill J, Aston C, Palmer S. Adams–Oliver syndrome review of the literature: refining the diagnostic phenotype. Am J Med Genet Part A. 2017;173:790–800.CrossRefPubMed Hassed S, Li S, Mulvihill J, Aston C, Palmer S. Adams–Oliver syndrome review of the literature: refining the diagnostic phenotype. Am J Med Genet Part A. 2017;173:790–800.CrossRefPubMed
3.
go back to reference Gala MK, Mizukami Y, Le LP, et al. Germline mutations in oncogene-induced senescence pathways are associated with multiple sessile serrated adenomas. Gastroenterology. 2014;146:520–529.CrossRefPubMedPubMedCentral Gala MK, Mizukami Y, Le LP, et al. Germline mutations in oncogene-induced senescence pathways are associated with multiple sessile serrated adenomas. Gastroenterology. 2014;146:520–529.CrossRefPubMedPubMedCentral
4.
go back to reference Sanada Y, Mizuta K, Niki T, et al. Hepatocellular nodules resulting from congenital extrahepatic portosystemic shunts can differentiate into potentially malignant hepatocellular adenomas. J Hepatobiliary Pancreat Sci. 2015;22:746–756.CrossRefPubMed Sanada Y, Mizuta K, Niki T, et al. Hepatocellular nodules resulting from congenital extrahepatic portosystemic shunts can differentiate into potentially malignant hepatocellular adenomas. J Hepatobiliary Pancreat Sci. 2015;22:746–756.CrossRefPubMed
6.
go back to reference Sempoux C, Paradis V, Komuta M, et al. Hepatocellular nodules expressing markers of hepatocellular adenomas in Budd–Chiari syndrome and other rare hepatic vascular disorders. J Hepatol. 2015;63:1173–1180.CrossRefPubMed Sempoux C, Paradis V, Komuta M, et al. Hepatocellular nodules expressing markers of hepatocellular adenomas in Budd–Chiari syndrome and other rare hepatic vascular disorders. J Hepatol. 2015;63:1173–1180.CrossRefPubMed
7.
go back to reference Sorkin T, Strautnieks S, Foskett P, et al. Multiple B-catenin mutations in hepatocellular lesions arising in Abernethy malformation. Hum Pathol. 2016;53:153–158.CrossRefPubMed Sorkin T, Strautnieks S, Foskett P, et al. Multiple B-catenin mutations in hepatocellular lesions arising in Abernethy malformation. Hum Pathol. 2016;53:153–158.CrossRefPubMed
8.
go back to reference Liu Z, Fan F, Wang A, Zheng S, Lu Y. DLL4-Notch signaling in regulation of tumor angiogenesis. J Cancer Res Clin Oncol. 2014;140:525–536.CrossRefPubMed Liu Z, Fan F, Wang A, Zheng S, Lu Y. DLL4-Notch signaling in regulation of tumor angiogenesis. J Cancer Res Clin Oncol. 2014;140:525–536.CrossRefPubMed
Metadata
Title
Growing Concerns: A 3-Year-Old Girl with Multiple Hepatic Masses and Gastrointestinal Bleeding
Authors
Christine Yang
Adam Gomez
Anshul Haldipur
William Berquist
Dorsey Bass
Publication date
01-02-2018
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 2/2018
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-017-4644-5

Other articles of this Issue 2/2018

Digestive Diseases and Sciences 2/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine